Alto Neuroscience Inc.
Symbol: ANRO (NYSE)
10.13
▼ (-6.68%) -0.725
Company Description:
Alto Neuroscience Inc is a clinical-stage biopharmaceutical company with a mission to redefine psychiatry by leveraging individuals' neurobiology to develop personalized and effective treatment options. The company currently consists of different clinical-stage assets such as ALTO-100, ALTO-202, ALTO-101, and ALTO-300 among others initially targeting depressive disorders and schizophrenia populations as identified by independent brain-based biomarkers.
Key Stats
- Today's Open: $10.58
- Today's High: $10.95
- Today's Low: $9.735
- Today's Volume: 452.04K
- Yesterday Close: $10.85
- Yesterday High: $11.44
- Yesterday Low: $10.53
- Yesterday Volume: 1.07M
- Last Min Volume: 538
- Last Min High: $10.125
- Last Min Low: $10.124
- Last Min VWAP: $10.125
Company Profile
- Name: Alto Neuroscience Inc.
- Website: https://www.altoneuroscience.com
- Listed Date: 2024-02-02
- Location: MOUNTAIN VIEW, CA
- Market Status: Active
- CIK Number: 0001999480
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $293.78M
- Round Lot: 100
- Outstanding Shares: 27.08M
- Asset Type: CS
RECENT FILINGS FOR ANRO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-20 | 8-K | View |
| 2025-10-10 | SCHEDULE 13G | View |
| 2025-08-14 | SCHEDULE 13G/A | View |
| 2025-08-14 | 4 | View |
| 2025-08-14 | 3 | View |
| 2025-08-13 | 10-Q | View |
| 2025-08-13 | 8-K | View |
| 2025-07-16 | SCHEDULE 13G/A | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 4 | View |
| 2025-07-08 | 8-K | View |
| 2025-06-26 | 8-K | View |
| 2025-06-03 | 8-K | View |
| 2025-05-15 | SCHEDULE 13G/A | View |
| 2025-05-15 | 4 | View |
| 2025-05-15 | 4 | View |
| 2025-05-15 | 4 | View |
| 2025-05-15 | 4 | View |
Latest News on ANRO